Neoadjuvant Chemoradiotherapy plus Surgery for Esophageal Sq
In this study, long-term outcomes demonstrated a survival benefit from neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for the treatment of patients with locally advanced esophageal squamous cell carcinoma (ESCC), indicating that this combination may be considered a standard of care in this patient population.

The objective of this study was to compare the treatment efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery with surgery alone for long-term survival among patients with locally advanced ESCC.

The Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 study was a multicenter open-label randomized phase 3 clinical trial. A total of 451 patients aged 18 to 70 years with thoracic ESCC stage T1-4N1M0/T4N0M0 were enrolled and randomized.

- Patients receiving NCRT plus surgery had prolonged overall survival compared with those receiving surgery alone, with a 5-year survival rate of 59.9%, respectively.

- Patients in the NCRT group compared with the surgery group also had prolonged disease-free survival, with a 5-year survival rate of 63.6%, respectively.

In particular, treatment with NCRT plus surgery significantly improved long-term overall survival and disease-free survival and therefore may be considered a standard of care for patients with locally advanced ESCC.

JAMA Surgery